SAN DIEGO — Patients receiving budesonide orodispersible tablets for the treatment of eosinophilic esophagitis were able to maintain remission through 48 weeks, according to study results presented at Digestive Disease Week.
Alfredo Lucendo, MD, of the department of gastroenterology at Hospital General de Tomelloso in Spain, said previous studies have shown that budesonide orodispersible tablets (BOT) induce remission in patients with EoE.
“This maintenance of remission trial had the primary goal to assess the efficacy of two doses of this novel formulation of budesonide compared to

Source link